The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Open accessAbstract
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surgical resection is recognized worldwide as the preferred treatment for patients with early stage HCC, whereas liver transplantation is indicated in those with early stage disease who are not deemed suitable for resection7,22.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, regimens including immune-checkpoint inhibitors (ICIs) are currently adopted as first-line therapies in clinical guidelines7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Currently, clinical decisions are based on clinical factors including, but not limited to, performance status, tumour burden, liver function and comorbidities7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Now the positive results of IMbrave 050 (ref. 12) have led to a revised management algorithm for patients with early stage HCC by incorporating adjuvant therapies in this disease setting7 (Fig. 4).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“[309] mRECIST criteria has been proposed to adapt RECIST criteria to particularities of HCC, enabling capture of antitumoral response without observed shrinkage after local and systemic therapies.”
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationErdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
InfluentialMazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · cited 1×
“[206] 211] The main barrier to LT is a shortage of available liver allografts compared with demand, prompting an allocation system that directs access to deceased donor organs for patients both with and without HCC.”
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationCancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 6,308
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“[320] In 2018, lenvatinib (an oral mTKI targeting vascular endothelial growth factor [VEGF]2 and other kinases) met its primary endpoint of noninferiority versus sorafenib in a global phase III randomized study, REFLECT.”
Research works printed but not linked: 2
- Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
- Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057
Cited by
Sorted by citations
Items 301–400 of 1,000
Wagle, N. S., Park, S., Washburn, D. J., Ohsfeldt, R. L., Kum, H., & Singal, A. G. (2024) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-23-1236 · Cited by 12
Self-citationRecent Advances in Ablative Therapies for Hepatocellular Carcinoma
Zahra, S. A., Nadeem, A., Kundu, A., Gibson, N., Haggaz, A., Sato, K. T., Lewandowski, R. J., & Gordon, A. C. (2025) · Cancers · doi:10.3390/cancers17193251 · Cited by 11
Impact of LEAP-012 and EMERALD-1 in the management of HCC
Singal, A. G., Garcia-Reyes, K., Kelley, R. K., & Kim, E. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101664 · Cited by 11
“3,4 Recent advances in treatment options, particularly the introduction of immune checkpoint inhibitors (ICIs), have significantly improved prognosis for patients with advanced-stage HCC. 5 Activity in advanced stages of HCC has spurred interest in evaluating ICIs in earlier lines of therapy,…”
Self-citationYang, K., Lee, J., Jang, J. W., Yoon, S. K., Sung, P. S., & Han, J. W. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004855 · Cited by 11
“…clinical input variables alongside standardized prompts explicitly referencing the AASLD and EASL guidelines that were current at the time of each patient’s diagnosis ensuring temporal consistency between the registry data and the reference standards used for training and evaluation [4,5].”
Huang, C., Xiao, X., Zhou, L., Chen, F., Wang, J., Hu, X., & Gao, C. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24990 · Cited by 11
Systemic therapies in hepatocellular carcinoma: A revolution?
Fortuny, M., Sanduzzi‐Zamparelli, M., & Reig, M. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12510 · Cited by 10
Vitale, A., Angelico, R., Sensi, B., Lai, Q., Kauffmann, E. F., Scalera, I., Serenari, M., Ginesini, M., Romano, P., Furlanetto, A., et al. (2024) · Cancers · doi:10.3390/cancers16050966 · Cited by 12
“In selected patients with cirrhosis, liver transplantation (LT) represents the gold standard treatment for non-resectable HCC tumors [23].”
BackgroundDong, M., Li, C., Zhang, L., Zhou, J., Xiao, Y., Zhang, T., Jin, X., Fang, Z., Zhang, L., Han, Y., et al. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29428 · Cited by 11
Role of biomarkers in the diagnosis and management of HCC
Al-Hasan, M., Mehta, N. J., Yang, J. D., & Singal, A. G. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000398 · Cited by 11
“[14,15] HCC surveillance is associated with improved early tumor detection, curative treatment, and overall survival.”
Self-citationUrquijo-Ponce, J. J., Mateu, C. A., Sánchez, M. L., Castelló-Miralles, I., & Diago, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i19.2512 · Cited by 13
Kuon-Yeng, C., Xiao, T. S., Nagaraj, R. U., Savsani, E., Mohammed, A., Li, J., Lyshchik, A. P., Liu, J., Wessner, C. E., Tahmasebi, A., et al. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.06.005 · Cited by 11
Bae, S. H., Jang, W. I., Mortensen, H. R., Weber, B., Kim, M., & Høyer, M. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.06.26 · Cited by 11
“Sanford et al. 32 compared PBT and photon RT in 133 patients with unresectable HCC. PBT decreased the risk of non-classic RILD (odds ratio, 0.26; P =0.03; 95% CI, 0.08-0.86).”
InfluentialWu, K., Lee, I., Chi, C., Liu, C., Chiu, N., Hsu, S., Lee, P., Wu, C., Luo, J., Hou, M., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18199 · Cited by 11
“3,7 Identification of predictive markers for HCC recurrence after RFA remains a critical challenge in clinical practice.”
Lee, I., Lei, H.-J., Wang, L.-C., Yeh, Y., Chau, G., Hsia, C., Chou, S., Luo, J., Hou, M., & Huang, Y. (2024) · Liver Cancer · doi:10.1159/000540802 · Cited by 11
“However, the recurrence rates, particularly within the fi rst 2 years post-resection, remain alarmingly high, ranging from 50% to 70% at the 5-year mark [4 – 6].”
Singal, A. G., Daher, D., Narasimman, M., Yekkaluri, S., Liu, Y., Cerda, V., Banala, C., Khan, A., Lee, M., Dahan, K. S. E., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae228 · Cited by 10
Self-citationThe Diagnosis and Staging of Hepatocellular Carcinoma
Vutien, P., Kim, N. J., & Nguyen, M. H. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.007 · Cited by 11
Cho, E., Law, M., Yu, Z.-N., Yong, J. N., Tan, C., Tan, E., Takahashi, H., Danpanichkul, P., Nah, B., Soon, G., et al. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08747-5 · Cited by 6
Li, X., Qian, Y., Lu, X., Xu, M., He, S., Zhang, J., & Song, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.064 · Cited by 11
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
Suzuki, H., Fujiwara, N., Singal, A. G., Baumert, T. F., Chung, R. T., Kawaguchi, T., & Hoshida, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001227 · Cited by 11
Self-citationWang, Y., Chi, S., Tian, Y., Li, X., Zhang, H., Xu, Y., Huang, C., Gao, Y., Jin, G., Fu, Q., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002281 · Cited by 13
“Currently, B-mode ultrasound, computed tomography (CT), magnetic resonance imaging, and tumor markers such as alpha-fetoprotein (AFP) are used to detect HCC [ 4 ] .”
Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies
Takamoto, T., Mihara, Y., Nishioka, Y., Ichida, A., Kawaguchi, Y., Akamatsu, N., & Hasegawa, K. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02703-7 · Cited by 11
Lü, D., Li, H., Sun, P., Tian, J., Jiao, K., Cao, Q., Wang, Y., Jia, J., He, Q., Peng, S.-X., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002326 · Cited by 13
“…observed that HAIC-combined systemic therapy appeared to confer greater benefits in treating HCC patients with main portal vein invasion compared to those without PVTT, suggesting the potential complementary effect of HAIC to systemic therapies in addressing this challenging clinical issue [ 52 ] .”
Cao, J., Dong, Y., Xu, X., Zhang, Q., Wang, W., Möller, K., & Dietrich, C. F. (2025) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2025.04.018 · Cited by 11
Updates on Liquid Biopsy and ctDNA in Transplant Oncology
Loszko, A. F., Byrne, M., Jiménez-Soto, C., Tomiyama, K., Bekki, Y., & Hernandez‐Alejandro, R. (2025) · Cancers · doi:10.3390/cancers17121930 · Cited by 11
Kim, D. W., Chang, W., Kim, S. Y., Lim, Y., Choi, J., Cho, J., Kim, J.-W., Cho, J. Y., Jeon, S. K., Lee, Y. B., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0258 · Cited by 11
Nam, H., Kim, D. Y., Kim, D. Y., Kim, J. H., Kim, C. W., Lee, J., Yang, K., Han, J. W., Sung, P. S., Yoon, S. K., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001444 · Cited by 11
Allaire, M., da Fonseca, L. G., Sanduzzi‐Zamparelli, M., Choi, W., Monge, C., Liu, K., Leibfried, M., Manes, S., Maravic, Z., Mishkovikj, M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101408 · Cited by 12
Novel urine cell-free DNA methylation markers for hepatocellular carcinoma
Lin, S. Y., Xia, W., Kim, A. K., Chen, D., Schleyer, S., Choi, L., Wang, Z., Hamilton, J. P., Luu, H. T., HANN, H.-W. L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48500-y · Cited by 12
Nguyen, T. A., Shin, Y., Ruppa, A., Krall, A. S., Pham, J., Chen, P.-C., Mirmohammadi, H., Keshavarz, P., Finn, R. S., Agopian, V. G., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001391 · Cited by 10
Self-citationLi, Q., Shi, J., Ruan, X., Zhang, L., Fu, R., Hidayat, K., Qin, L., Xu, J., Chong, Y., & Hu, C. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202510798 · Cited by 11
Nevi, L., Aiello, C., Molinaro, F., Altomare, A., Musarra, T., Gallo, P., Taffon, C., Guarino, M. P. L., Gentilucci, U. V., Baiocchini, A., et al. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00038-8 · Cited by 13
“Additionally, the sensitivity of ultrasound depends on the operator ’ s experience, which can lead to variability in results 1,4 .”
InfluentialGlobal Cancer Imaging Access: Addressing Barriers and Harnessing Innovations
Hussain, H. K., Rajeev, R., DeStigter, K. K., & Gulani, V. (2025) · Radiology Imaging Cancer · doi:10.1148/rycan.250019 · Cited by 10
Tian, B., Yan, L., & Liang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1695861 · Cited by 11
Fang, J., Zhong, S., Wang, T., He, K., Mu, A., Ong, M., Lin, Y., Zhu, Z., Wang, N., Wu, J., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-336719 · Cited by 10
“48 By contrast, for patients beyond selection criteria, conventional treatments like TACE alone achieve only limited success in downstaging.”
Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma
Hussain, M. M., Bi, F., Wang, J., Zhai, A., Li, F., & Hu, H. (2025) · Cancer Medicine · doi:10.1002/cam4.71330 · Cited by 11
Liu, Y., Cong, K., Li, Q., Zhang, D., & Sheng, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1741398 · Cited by 12
“For Child-Pugh C patients, supportive care and liver transplantation are primarily recommended, with routine systemic therapy not advised (172).”
Jeng, W., Yip, T. C., & Lok, A. S.-F. (2026) · JAMA · doi:10.1001/jama.2026.6070 · Cited by 16
Marrone, G., Leone, M. S., Biolato, M., Liguori, A., Bianco, G., Spoletini, G., Gasbarrini, A., Miele, L., & Pompili, M. (2023) · Cancers · doi:10.3390/cancers15235593 · Cited by 10
“In subjects undergoing liver resection for HCC, current guidelines suggest indefinite cross-sectional imaging examinations of the abdomen and chest plus serum AFP every 3–6 months [56].”
BackgroundMourad, S. N., la Garza‐Ramos, C. D., & Toskich, B. B. (2024) · Cancers · doi:10.3390/cancers16030669 · Cited by 10
“Patients with BCLC B-C disease or Child-Pugh B7-C liver function can be considered for radioembolization as a definitive therapy or as a bridging or downstaging to a transplant approach [1–3].”
BackgroundQuick and easy assessment of sarcopenia in cirrhosis: Can ultrasound be the solution?
Campani, F., Cavoli, T. V. L., Arena, U., Marra, F., Lynch, E. N., & Campani, C. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i17.2287 · Cited by 10
“Furthermore, abdominal US is used to screen cirrhotic patients for HCC semiannually, in accordance with guidelines of the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases[59,60].”
Blukacz, L., Nuciforo, S., Fucile, G., Trulsson, F., Duthaler, U., Wieland, S. F., & Heim, M. H. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000437 · Cited by 10
“Transarterial chemoembolization (TACE) is recommended for first-line treatment of intermediate-stage, unresectable HCC. [1] TACE is a locoregional therapy that combines the cytotoxic effect of a chemo-therapeutic agent with the ischemic effect of arterial embolization.”
Ma, L.-N., Ma, Y., Luo, X., Ma, Z.-M., Ma, L.-N., & Ding, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-62323-5 · Cited by 10
To, J. C., Ghosh, S., Zhao, X., Pasini, E., Fischer, S. E., Sapisochín, G., Ghanekar, A., Jaeckel, E., & Bhat, M. (2024) · Human Genomics · doi:10.1186/s40246-024-00624-6 · Cited by 10
“HCC recurrence after LT poses a significant clinical challenge, with reported rates of 10–20% in the first year after LT [5–8].”
BackgroundMohebbi, A., Kiani, I., Mohammadzadeh, S., Mohammadi, A., & Tavangar, S. M. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04302-y · Cited by 10
“[18F]-FDG, the main radiotracer used in PET scans, has a low sensitivity to diagnose HCC, according to the guidelines of the European Association for the Study of the Liver (EASL) [4] and the American Association for the Study of Liver Diseases (AASLD) [5].”
Recent Advances in Liver Transplantation for Hepatocellular Carcinoma
Li, P. J., Shah, S., & Mehta, N. J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01247-8 · Cited by 11
“Despite the development and availability of numerous prediction models that perform reasonably well, there currently lacks a consensus risk stratification tool and, subsequently, a standardized post-liver transplantation recurrence surveillance protocol and adjuvant therapy guideline [7, 56].”
BackgroundSelf-citationKang, W., Tang, P., Luo, Y.-G., Lian, Q., Zhou, X., Ren, J., Cong, T., Miao, L., Li, H., Huang, X.-Y., et al. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.10.038 · Cited by 9
Jiang, H., Li, B., Zheng, T., Qin, Y., Wu, Y., Wu, Z., Ronot, M., Chernyak, V., Fowler, K. J., Bashir, M. R., et al. (2024) · European Radiology · doi:10.1007/s00330-024-11295-1 · Cited by 12
Preventing the progression of cirrhosis to decompensation and death
Villanueva, C., Tripathi, D., & Bosch, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01031-x · Cited by 13
“Surveillance and management of HCC should be performed according to guidelines 113 .”
Fontan-Associated Liver Disease
Hilscher, M. B., & Johnson, J. N. (2025) · Seminars in Liver Disease · doi:10.1055/a-2556-4897 · Cited by 10
Khaled, N. B., Zarka, V., Hobeika, B., Schneider, J. A., Rau, M., Weich, A., Leicht, H. B., Ye, L., Piseddu, I., Dill, M. T., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70090 · Cited by 10
Lu, D., Zhou, L., Zuo, Z., Zhang, Z., Zheng, X., Weng, J., Yu, Z., Ji, J., & Xia, J. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s513696 · Cited by 10
“3,4 However, transarterial chemoembolization (TACE) remains the preferred initial therapy for patients afflicted with HCC plus PVTT (HCC-PVTT) in China, without extrahepatic metastases.”
Applications and challenges of patient-derived organoids in hepatobiliary and pancreatic cancers
Hu, J.-W., Pan, Y., Zhang, X., Li, J., & Jin, Y. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i20.106747 · Cited by 10
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
Akabane, M., Chatzipanagiotou, O. P., Imaoka, Y., Schenk, A. D., & Pawlik, T. M. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s528709 · Cited by 10
“1,15 Despite its curative intent, surgical resection is associated with a high risk of disease recurrence, ranging from 50% to 70% within five years.”
Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma
Guerra, P., Martini, A., Pontisso, P., & Angeli, P. (2023) · Cancers · doi:10.3390/cancers15143629 · Cited by 11
Do We Have a Winner? Advocating for SBRT in HCC Management
Safavi, A. H., Dawson, L. A., & Mesci, A. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100740 · Cited by 10
“These range from recommended use of SBRT by the American Association for the Study of Liver Diseases (AASLD) and the American Society for Radiation Oncology (ASTRO) to omission of radiotherapy by the Barcelona Clinic Liver Cancer (BCLC) group [2 – 5].”
MethodSelf-citationLiver transplantation and primary liver cancer in porphyria
Lissing, M., Wang, B., & Wåhlin, S. (2024) · Liver International · doi:10.1111/liv.15894 · Cited by 12
“The use of alpha-fetoprotein (AFP) in HCC-surveillance in gen - eral is debated 78,79 and the limited data on AFP from patients with AP and PLC is inconclusive.”
Kim, D. H., & Choi, S. H. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.04.05 · Cited by 9
Chu, C., Chen, H., Lin, P., Cheng, C., Kuo, H., Fan, P.-H., Peng, W., & Wu, L. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16674 · Cited by 9
“Approved systemic therapies include ICIs and antiangiogenic targeted therapies, 20 wherein ICIs exhibit better overall survival than antiangiogenic targeted therapies.”
Tamaki, N., Mori, N., Takaki, S., Tsuji, K., Tada, T., Nakamura, S., Ochi, H., Mashiba, T., Doisaki, M., Marusawa, H., et al. (2024) · Anticancer Research · doi:10.21873/anticanres.17219 · Cited by 9
Adalı, G., Aykut, H., Bilgiç, N. M., & Yilmaz, Y. N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37990 · Cited by 9
El‐Serag, H. B., Thrift, A. P., Duong, H. T., Ning, J., Khaderi, S. A., Singal, A. G., Asrani, S. K., Marrero, J. A., Powell, H., Rizwan, K., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000545 · Cited by 9
“HCC was defined according to AASLD criteria, [17,18] including histological or radiological diagnosis using characteristic appearance (arterial enhancement and delayed washout of contrast) on triple-phase computerized tomography or MRI (LI-RAD 5) or those with suspicious lesions (LI-RAD 4) that…”
MethodSelf-citationZhao, K., Karimi, A., Kelly, L., Petre, E. N., Marinelli, B. S., Alexander, E. S., Sotirchos, V. S., Erinjeri, J. P., Covey, A. M., Sofocleous, C. T., et al. (2025) · Current Oncology · doi:10.3390/curroncol32010051 · Cited by 9
“However, the existing data are scant, partly because histologic confirmation is not always necessary for a diagnosis of HCC, and tissue sampling comes with risks of bleeding and tumor seeding [17].”
Evolving epidemiology of HCC in Spain
Sala, M., Pascual, S., Roca, M. R. R., Matilla, A. M., Campos, M., Delgado, M. B., Ferrer, M. T., Montero, J. L., Santiago, J. M. G., Guerrero, A. F., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101336 · Cited by 10
Kokudo, T., & Kokudo, N. (2025) · Cancers · doi:10.3390/cancers17030507 · Cited by 9
“In the AASLD criteria, the UCSF criteria, total tumor volume cutoff of 115 cm, Up-To-Seven criteria, extended Toronto criteria, and Kyoto criteria are also proposed as the expanded criteria [56].”
Dahan, K. S. E., Yokoo, T., Daher, D., Davenport, M. S., Fetzer, D. T., Mendiratta‐Lala, M., Rich, N. E., Yang, E., Parikh, N. D., & Singal, A. G. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101357 · Cited by 9
Self-citationHeo, S., Jeong, B., Lee, S. S., Kim, M., Jang, H. J., Choi, S. J., Kim, K. M., Ha, T., & Jung, D. (2025) · European Radiology · doi:10.1007/s00330-025-11411-9 · Cited by 9
Yang, M. J., Li, G., Chen, K., Wu, Y., Sun, T., & Wang, W. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002302 · Cited by 9
“Both LR and RFA are recommended as primary treatment strategies in several international guidelines for solitary small HCC, including the 5th JSH-HCC Guidelines [4] , AASLD Practice Guidance [5] , and 2022 Chinese clinical guidelines [6] .”
Bardhi, O., Daher, D., Patel, M. J., Dahan, K. S. E., Rich, N. E., Mitta, S., Parikh, N. D., Pillai, A. A., Kulik, L., Yang, J. D., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101368 · Cited by 10
Self-citationMishra, A., Valentin, E. M. D. S., Barcena, A. J. R., Bolinas, D. K. M., Bernardino, M. R., Canlas, G. M., Ricks, K. A., Damasco, J. A., & Melancon, M. P. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c21949 · Cited by 9
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma
Shiina, S., Tateishi, R., Choi, J. I., Kim, S. Y., Meng, Z., Shen, L., Lu, S., Hwang, J.-I., Tobari, M., Maruyama, H., et al. (2025) · Liver Cancer · doi:10.1159/000544976 · Cited by 11
“Extrahepatic spread or vascular invasion cases are not traditionally considered indications for ablation [18, 22, 23] as these conditions generally preclude curative treatment.”
Outla, Z., Oyman-Eyrilmez, G., Korelova, K., Přechová, M., Frick, L. D., Sarnová, L., Bisht, P., Novotná, P., Kosla, J., Bortel, P., et al. (2025) · eLife · doi:10.7554/elife.102205.3 · Cited by 9
Cui, X., Cao, C., Hao, W., Pan, X., Cao, Y., Fu, Y., Hao, H., Jiao, Y., Lin, S., Cui, S., et al. (2025) · Small · doi:10.1002/smll.202500144 · Cited by 9
Piñero, F., Anders, M., Bermúdez, C., Arufe, D., Varón, A., Palazzo, A., Rodriguez, J., Beltrán, O., Simian, D., da Fonseca, L. G., et al. (2025) · Liver International · doi:10.1111/liv.70092 · Cited by 9
“…either with Computerised Axial Tomography (CT) or Magnetic Resonance Imaging (MRI), or histological diagnosis, according to international guidelines [23–26]; (2) Locally advanced (non-surgical) or metastatic HCC, classified as BCLC stage A (treatment stage migration), B, or C at study enrollment.”
Singal, A. G., Yang, J. D., Jalal, P. K., Salgia, R. J., Mehta, N. J., Hoteit, M. A., Kao, K., Daher, D., Dahan, K. S. E., Hernandez, P., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003494 · Cited by 9
Self-citationYang, D.-L., Peng, N., Nong, J.-L., Chen, K., Su, Z., Yu, Y., Ye, L., Zeng, F.-J., Liu, S., Yan, Y.-H., et al. (2025) · Liver Cancer · doi:10.1159/000546052 · Cited by 9
“…June 30, 2023 and if they (1) were 18 – 75 years old at the time of conversion therapy, (2) had been de fi nitively diagnosed with HCC as described [18], (3) had HCC that was initially deemed unresectable but later resectable after partial or complete response to conversion therapy (see next…”
LI-RADS CT/MRI Treatment Response Assessment Update in 2024
Shin, J., Gu, K., & Min, J. H. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2025.0028 · Cited by 9
Hatanaka, T., Yata, Y., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Liver International · doi:10.1111/liv.70192 · Cited by 9
Lee, I., Wang, H.-W., Teng, W., Lin, T., Chen, C.-H., Lai, H., Lee, T., Chang, C.-W., Hung, C., Dai, C., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0724 · Cited by 11
Mesropian, A., Gris‐Oliver, A., Balaseviciute, U., Potdar, A. A., Kimura, T., Shen, J., Torres-Marcén, M., Abril‐Fornaguera, J., Piqué‐Gili, M., Camell-Raventos, D., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0725 · Cited by 10
Self-citationLu, H., Wang, Q., Tian, Q., Liang, X., Liu, J., Chen, J., Wang, D., & Wang, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114244 · Cited by 9
Navigating second-line therapy after immunotherapy in advanced HCC☆
Vogel, A., Saborowski, A. L., Rimassa, L., & El-Khoueiry, A. B. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101630 · Cited by 9
Jia, X., Jiang, H., Ye, Z., Wei, H., Chen, J., Qu, Y., Sirlin, C. B., Song, B., & Wang, Y. (2025) · European Radiology · doi:10.1007/s00330-025-12075-1 · Cited by 9
Chang, Y.-P., Chen, Y.-C., Cheng, P., Fang, Y., Chen, C.-Y., Kao, W., Lin, C., Yang, S.-S., Shih, Y. L., Peng, C., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337275 · Cited by 9
Chronic Liver Disease in the Older Patient—Evaluation and Management
DiLeo, D. A., Gidener, T., & Aytaman, A. (2023) · Current Gastroenterology Reports · doi:10.1007/s11894-023-00908-2 · Cited by 11
“Systemic therapy should be offered to patients with pre-served liver function not amenable to or progressing after locoregional therapy [76].”
InfluentialIntermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?
Stefanini, B., Ielasi, L., Pallotta, D. P., Penazza, S., Marseglia, M., & Piscaglia, F. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.02.21 · Cited by 9
“16,17 Despite its widespread adoption, the BCLC classification system has faced criticisms over the years.”
BackgroundQadeer, M. A., Abbas, Z., Amjad, S., Shahid, B., Altaf, A., & Siyal, M. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i1.90893 · Cited by 9
Systemic Therapies for Hepatocellular Carcinoma in India
Jahagirdar, V., Rama, K., Habeeb, M., Sharma, M., Rao, P. N., Reddy, D. N., Singal, A. G., & Kulkarni, A. V. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101440 · Cited by 9
Self-citationFactors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Lee, Y., Karim, M. A., Kum, H., Park, S., Rich, N. E., Noureddin, M., Singal, A. G., & Yang, J. D. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0450 · Cited by 9
Self-citationUrhuț, M. C., Săndulescu, L., Ciocâlteu, A., Cazacu, S. M., & Dănoiu, S. (2023) · Diagnostics · doi:10.3390/diagnostics13203288 · Cited by 9
“B-mode ultrasound is proposed in international society guidelines as the main surveillance tool for patients at risk of developing HCCs [25,26].”
Yoon, J. H., Park, J. Y., Lee, S. M., Lee, E. S., Kim, J. H., & Lee, J. M. (2023) · Cancer Imaging · doi:10.1186/s40644-023-00616-0 · Cited by 8
Zhou, Z., Liu, Q., Liu, J., Li, W., Cao, S., Xu, J., Chen, J., Xu, X., & Chen, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30622 · Cited by 8
“Liver transplantation (LT) can cure HCC and underlying liver disease and is the best treatment strategy for patients with early-stage HCC with multifocal tumors or hepatic dysfunction who are not candidates for hepatectomy [5].”
BackgroundInfluentialSingal, A. G., Chhatwal, J., Parikh, N. D., & Tapper, E. B. (2024) · Liver Cancer · doi:10.1159/000539895 · Cited by 9
Self-citationRecent advances in surgical management strategies for hepatocellular carcinoma
Ding, Z., Shi, Y., Chen, J., Fan, J., & Zhou, J. (2024) · hLife · doi:10.1016/j.hlife.2024.06.007 · Cited by 8
“Conversion therapy for HCC mainly involves two arms: one for oncologically un-resectable patients, whereby a better prognosis cannot be obtained after surgical treatment, and the other for technically unresectable patients [8,62].”
Louissaint, J., Kyalwazi, B., Deng, J. J., Melendez-Torres, J., Turer, R. W., Hogan, T. P., Tapper, E. B., Yekkaluri, S., Xie, D., Rich, N. E., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002940 · Cited by 8
“Patients with cirrhosis undergo semiannual liver imaging for hepatocellular carcinoma (HCC) surveillance, which has the potential to detect abnormal lesions, including new HCC diagnoses (5,6).”
Self-citationCantero, M. J., Bueloni, B., Llamazares, L. G., Fiore, E. J., Mauriz, L. L., Atorrasagasti, C., Mazzolini, G. D., Malvicini, M., Bayo, J., & García, M. G. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03806-0 · Cited by 8
“Since most patients receive only palliative treatments, new therapeutic approaches are needed [28].”
BackgroundAdvances in the management of complications from cirrhosis
Singh, J., Ebaid, M., & Saab, S. (2023) · Gastroenterology report · doi:10.1093/gastro/goae072 · Cited by 8
Wang, Y., Qu, Y., Yang, C., Wu, Y., Wei, H., Qin, Y., Yang, J., Zheng, T., Chen, J., Cannella, R., et al. (2024) · European Radiology · doi:10.1007/s00330-024-11043-5 · Cited by 8
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma
Stefanini, B., Manfredi, G. F., D’Alessio, A., Fulgenzi, C. A. M., Awosika, N. O., Celsa, C., Pirisi, M., Rigamonti, C., Burlone, M. E., Vincenzi, F., et al. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2419519 · Cited by 8
Xu, X.-Y., Wang, Z., Liu, C.-Y., Wu, H.-D., Hu, Z.-X., Lin, Y.-Y., Zhang, S., Shen, J., Zhong, B., & Zhu, X. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s487472 · Cited by 8
Kanneganti, M., Al-Hasan, M., Bourque, S., Deodhar, S., Yang, J. D., Huang, D. Q., Kulkarni, A. V., Gopal, P., Parikh, N. D., Kanwal, F., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.10.015 · Cited by 8
Self-citation
Metadata
- Authors
- Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- University Health Network (CA)
- Oregon Health & Science University (US)
- Northwestern Medical Faculty Foundation (US)
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
- Vanderbilt University Medical Center (US)
- Medical College of Wisconsin (US)
- Stanford Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Corresponding author
- Singal, Amit G.
- ORCID
- Venue
- Hepatology
- Published
- 2023-05-22
- Volume
- 78
- Issue
- 6
- Pages
- 1922-1965
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10663390
- OpenAlex
- W4377011124
- Cited by
- 2,052
- References
- 341
- Citations by year
- 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
- FWCI
- 346.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- American Association for the Study of Liver Diseases
- Gilead Sciences
- Boston Scientific Corporation
- Exelixis
- Incyte
- Cancer Research UK (26813)
- Eisai
- Ipsen
- Sirtex Medical
- National Institutes of Health (UL1TR001863)
- Genentech
- National Cancer Institute (P50CA062924, R01CA285544)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
- MeSH terms
- Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
